Neuroscience Therapy Corporation Announces Business Strategy
LAS VEGAS, NV, April 6 /PRNewswire-FirstCall/ - Neuroscience Therapy Corp. announced today its business strategy, which is designed to place the Company at the top of the fast-growing neurostimulation market with its leading product P-Stim(TM).
The Company's strategy is as follows: 1. Gain credibility with pain management specialists: This will be achieved by conducting clinical trials and Phase IV studies to demonstrate the safety and effectiveness of P-Stim through evidence based medicine. 2. Focus on target markets: Initially concentrate on four main types of chronic pain and targeted selected physicians specializing in pain management. Focus will also include pain management practices in nine states. 3. Provide high quality product education: Training will be conducted by high profile pain management physicians from prestigious institutions across the country. 4. Develop and provide a strong product identity: Strong marketing and promotional campaigns will be utilized in the professional segment. 5. Provide practice development consulting services: Practice development consulting will be provided to customers that purchase P-Stim. The goals will be to prepare them for the introduction of P-Stim in their practice, help them maximize reimbursement and help them to generate incremental revenue.
With the neurostimulation market being in its infancy, according to the Wall Street Journal, Neuroscience believes this strategy will enable the Company to grow concurrently with the market and make substantial revenues.
About Neuroscience Therapy Corporation:
Neuroscience Therapy Corporation's operations are located in Southern California. It holds the rights to a new, safe and innovative technology to relieve pain. Its product portfolio consists of two complimentary products: the P-Stim(TM) Electro Stimulation Device and the Multi-Point(TM) Stylus. These products have no known side effects, unlike many pharmaceutical pain relievers. The neurostimulation market is in its infancy and could reach several billion dollars in sales. The Company is working toward being a leader in this market. For more information about Neuroscience Therapy Corp., visit: www.neurosciencetherapy.com .
Legal Notice Regarding Forward Looking Statements
The statements in this press release that relate to the Company's expectations with regard to the future impact on the Company's results are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this document may also contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results.
CONTACT: Ray Johnson, Investor Relations, 1-866-639-3900
Neuroscience Therapy CorporationCONTACT: Ray Johnson, Investor Relations, 1-866-639-3900